We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Expanding MedSun Program To Better Track Adverse Events
FDA Expanding MedSun Program To Better Track Adverse Events
April 1, 2011
BALTIMORE — The FDA is expanding its medical product surveillance network (MedSun) to better track adverse events, a move that comes shortly after the Office of Inspector General (OIG) said CDRH has failed to act on several recommendations for adverse event followup.